Drug companies line up to make deals with Trump after initial hesitation

When President Donald Trump declared in May that he wanted drug companies to voluntarily cut their prices, few pharmaceutical executives wanted to go first. Now, no one wants to be last – and risk the ...

New York State's 2025 Emerging Technology Advisory Board Releases Final Report to Boost Biotech Innovation, Commercialization and Public Health Impact

The final report, presented to New York Governor Kathy Hochul, outlines a path to translate investments in the state's biotech ecosystem into real-world outcomes. -- Executives from The Michael J. Fox ...

Pfizer (PFE) CEO’s Struggling Because Of “a Good Hand,” Says Jim Cramer

Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them.

Merck (MRK)’s CEO Has a “Better Hand,” Says Jim Cramer

We recently published 12 Stocks on Jim Cramer’s Radar . Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s ...

Pfizer: 2026 Feels Like Another Lost Year After Yesterday's Guidance Update

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...
BioSpace

Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites

For one, interest rates are finally going down, with the Federal Reserve executing its latest cut on December 10. And ...

Pfizer's stock drops after drug giant lowers its revenue forecast

Pfizer revised its revenue expectations for 2025 and detailed its outlook for 2026. Pfizer said revenue should come in at the lower end of its guidance for this year, while it expects less revenue in ...

Pfizer CEO defends vaccines, promises growth by end of decade

Pfizer CEO Albert Bourla called vaccine skepticism in the highest levels of the federal government “an anomaly” during an investor call on Tuesday. “We will continue investing in vaccines because, as ...
BioSpace

Pfizer CEO Blasts HHS’ Anti-Vaccine Policies as Revenue Outlook Dims

Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives ...
MediaPost

Pfizer CEO Takes Aim At Novo Nordisk In Obesity Drug Showdown

Pfizer’s battle with Novo Nordisk over control of obesity drug developer Metsera is getting nasty. After Pfizer apparently sealed a $4.9 billion purchase of Metsera in September, Novo Nordisk swooped ...
Forbes

Pfizer Bets Big On Obesity Market

Pfizer $4.9 billion cash acquisition of Metsera, a clinical-stage biotech focused on next-generation obesity drugs, is more than another high-profile deal in pharma’s dealmaking spree. It signals a ...
Futurism

RFK Jr. Sneezes Loudly While Trump Is Speaking

Infamously anti-mask, president Donald Trump was meeting with Pfizer CEO Albert Bourla and top health officials in the Oval Office when he was suddenly interrupted by his own secretary of health and ...